PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

Original languageEnglish (US)
Pages (from-to)139-148
Number of pages10
JournalFuture Cardiology
Volume12
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Hyperlipoproteinemia Type II
Life Style
Monoclonal Antibodies
Guidelines
Safety
Injections
Therapeutics
AMG 145

Keywords

  • alirocumab
  • evolocumab
  • LDL
  • monoclonal antibodies
  • PCSK9 inhibitors
  • statin intolerance

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A., Feinstein, M. J., Qamar, A., ... Martin, S. S. (2016). PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab. Future Cardiology, 12(2), 139-148. https://doi.org/10.2217/fca.15.89

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels : Evolocumab. / Dahagam, Chanukya; Goud, Aditya; Abdelqader, Abdelhai; Hendrani, Aditya; Feinstein, Matthew J.; Qamar, Arman; Joshi, Parag H.; Swiger, Kristopher J.; Byrne, Kathleen; Quispe, Renato; Jones, Steven R.; Blumenthal, Roger S.; Martin, Seth S.

In: Future Cardiology, Vol. 12, No. 2, 01.03.2016, p. 139-148.

Research output: Contribution to journalReview article

Dahagam, C, Goud, A, Abdelqader, A, Hendrani, A, Feinstein, MJ, Qamar, A, Joshi, PH, Swiger, KJ, Byrne, K, Quispe, R, Jones, SR, Blumenthal, RS & Martin, SS 2016, 'PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab', Future Cardiology, vol. 12, no. 2, pp. 139-148. https://doi.org/10.2217/fca.15.89
Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A et al. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab. Future Cardiology. 2016 Mar 1;12(2):139-148. https://doi.org/10.2217/fca.15.89
Dahagam, Chanukya ; Goud, Aditya ; Abdelqader, Abdelhai ; Hendrani, Aditya ; Feinstein, Matthew J. ; Qamar, Arman ; Joshi, Parag H. ; Swiger, Kristopher J. ; Byrne, Kathleen ; Quispe, Renato ; Jones, Steven R. ; Blumenthal, Roger S. ; Martin, Seth S. / PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels : Evolocumab. In: Future Cardiology. 2016 ; Vol. 12, No. 2. pp. 139-148.
@article{8d722a63686b4b9db2b8f9b05bedb5a0,
title = "PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Evolocumab",
abstract = "Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha{\circledR}), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.",
keywords = "alirocumab, evolocumab, LDL, monoclonal antibodies, PCSK9 inhibitors, statin intolerance",
author = "Chanukya Dahagam and Aditya Goud and Abdelhai Abdelqader and Aditya Hendrani and Feinstein, {Matthew J.} and Arman Qamar and Joshi, {Parag H.} and Swiger, {Kristopher J.} and Kathleen Byrne and Renato Quispe and Jones, {Steven R.} and Blumenthal, {Roger S.} and Martin, {Seth S.}",
year = "2016",
month = "3",
day = "1",
doi = "10.2217/fca.15.89",
language = "English (US)",
volume = "12",
pages = "139--148",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels

T2 - Evolocumab

AU - Dahagam, Chanukya

AU - Goud, Aditya

AU - Abdelqader, Abdelhai

AU - Hendrani, Aditya

AU - Feinstein, Matthew J.

AU - Qamar, Arman

AU - Joshi, Parag H.

AU - Swiger, Kristopher J.

AU - Byrne, Kathleen

AU - Quispe, Renato

AU - Jones, Steven R.

AU - Blumenthal, Roger S.

AU - Martin, Seth S.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

AB - Patients with familial hypercholesterolemia or statin intolerance are especially challenging to manage since LDL cholesterol levels often remain considerably elevated despite clinicians' best efforts. With statins regarded as first-line pharmacologic therapy by the current American College of Cardiology/American Heart Association guidelines to reduce LDL cholesterol and cardiovascular risk, there is now a critical need to determine when other agents will play a role beyond maximally tolerated statin therapy and lifestyle changes. In this review, we take a closer look at evolocumab (Repatha®), one of the new injectable human monoclonal antibodies to PCSK9 and its efficacy and safety properties from the results of various trials.

KW - alirocumab

KW - evolocumab

KW - LDL

KW - monoclonal antibodies

KW - PCSK9 inhibitors

KW - statin intolerance

UR - http://www.scopus.com/inward/record.url?scp=84959923543&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959923543&partnerID=8YFLogxK

U2 - 10.2217/fca.15.89

DO - 10.2217/fca.15.89

M3 - Review article

C2 - 26911578

AN - SCOPUS:84959923543

VL - 12

SP - 139

EP - 148

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -